AnaptysBio, Inc. is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company's ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ANAB
- CUSIP: N/A
- Web: www.anaptysbio.com
Capitalization:- Market Cap: $565.51 million
- Outstanding Shares: 20,269,000
Average Prices:- 50 Day Moving Avg: $24.81
- 200 Day Moving Avg: $24.62
- 52 Week Range: $15.17 - $30.71
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.85
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $11.82 million
- Price / Sales: 44.19
- Book Value: $5.44 per share
- Price / Book: 4.74
Profitability:Debt:- Debt-to-Equity Ratio: 0.12%
- Current Ratio: 13.56%
- Quick Ratio: 13.57%
Misc:- Average Volume: 51,378 shs.
- Short Ratio: 2.76
Frequently Asked Questions for AnaptysBio (NASDAQ:ANAB)
What is AnaptysBio's stock symbol?
AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."
How were AnaptysBio's earnings last quarter?
AnaptysBio, Inc. (NASDAQ:ANAB) announced its quarterly earnings data on Thursday, May, 11th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.57. View AnaptysBio's Earnings History.
Where is AnaptysBio's stock going? Where will AnaptysBio's stock price be in 2017?
5 analysts have issued 12-month price targets for AnaptysBio's shares. Their predictions range from $28.00 to $45.00. On average, they expect AnaptysBio's share price to reach $35.60 in the next year. View Analyst Ratings for AnaptysBio.
Who are some of AnaptysBio's key competitors?
Some companies that are related to AnaptysBio include Clinigen Group PLC (CLIN), Xencor (XNCR), Amarin Corporation PLC (AMRN), Insmed (INSM), Acorda Therapeutics (ACOR), Forward Pharma A/S (FWP), NeuroDerm (NDRM), Omeros Corporation (OMER), Aduro Biotech (ADRO), Synergy Pharmaceuticals (SGYP), Ascendis Pharma A/S (ASND), PTC Therapeutics (PTCT), Five Prime Therapeutics (FPRX), Insys Therapeutics (INSY), ZIOPHARM Oncology (ZIOP), Achaogen (AKAO), Keryx Biopharmaceuticals (KERX) and Aclaris Therapeutics (ACRS).
Who are AnaptysBio's key executives?
AnaptysBio's management team includes the folowing people:
- Hamza Suria, President, Chief Executive Officer, Director
- Dominic G. Piscitelli, Chief Financial Officer
- Matthew Moyle Ph.D., Chief Scientific Officer
- Marco Londei M.D., Chief Medical Officer
- Hollings C. Renton III, Lead Independent Director
- Carol G. Gallagher, Independent Director
- Nicholas Lydon Ph.D., Independent Director
- John P. Schmid, Independent Director
- James A. Schoeneck, Independent Director
When did AnaptysBio IPO?
(ANAB) raised $60 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
When did the company's lock-up period expire?
AnaptysBio's lock-up period expired on Tuesday, July 25th. AnaptysBio had issued 5,000,000 shares in its initial public offering on January 26th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. Since the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.
Who owns AnaptysBio stock?
AnaptysBio's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Hamilton Lane Advisors LLC (1.99%). Company insiders that own AnaptysBio stock include Healthcare Vii LP Frazier and Nicholas Lydon. View Institutional Ownership Trends for AnaptysBio.
How do I buy AnaptysBio stock?
Shares of AnaptysBio can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AnaptysBio's stock price today?
One share of AnaptysBio stock can currently be purchased for approximately $25.77.
MarketBeat Community Rating for AnaptysBio (NASDAQ ANAB)MarketBeat's community ratings are surveys of what our community members think about AnaptysBio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for AnaptysBio (NASDAQ:ANAB)Earnings History by Quarter for AnaptysBio (NASDAQ ANAB)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/11/2017 | Q1 2017 | ($0.18) | ($0.75) | $1.63 million | | View | N/A |  |
(Data available from 1/1/2011 forward)
Earnings Estimates for AnaptysBio (NASDAQ:ANAB)2017 EPS Consensus Estimate: ($1.94)
2018 EPS Consensus Estimate: ($2.95)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.24) | ($0.24) | ($0.24) |
| Q2 2017 | 1 | ($0.47) | ($0.47) | ($0.47) |
| Q3 2017 | 1 | ($0.56) | ($0.56) | ($0.56) |
| Q4 2017 | 1 | ($0.67) | ($0.67) | ($0.67) |
| Q1 2018 | 1 | ($0.60) | ($0.60) | ($0.60) |
| Q2 2018 | 1 | ($0.72) | ($0.72) | ($0.72) |
| Q3 2018 | 1 | ($0.83) | ($0.83) | ($0.83) |
| Q4 2018 | 1 | ($0.80) | ($0.80) | ($0.80) |
(Data provided by Zacks Investment Research)
Dividend History for AnaptysBio (NASDAQ:ANAB)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for AnaptysBio (NASDAQ:ANAB)Institutional Ownership Percentage: 72.59%
Insider Trades by Quarter for AnaptysBio (NASDAQ:ANAB)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 1/31/2017 | Healthcare Vii L.P. Frazier | Major Shareholder | Buy | 400,000 | $15.00 | $6,000,000.00 | |
| 1/31/2017 | Nicholas Lydon | Director | Buy | 16,666 | $15.00 | $249,990.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for AnaptysBio (NASDAQ:ANAB)
Latest Headlines for AnaptysBio (NASDAQ:ANAB)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to AnaptysBio, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 6:19 PM |
 | AnaptysBio, Inc.'s (NASDAQ:ANAB) Lock-Up Period Set To End on July 25th
www.americanbankingnews.com - July 18 at 10:49 AM |
| AnaptysBio, Inc. (NASDAQ:ANAB) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - July 17 at 4:04 PM |
| ETFs with exposure to AnaptysBio, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 5:42 PM |
| AnaptysBio, Inc. breached its 50 day moving average in a Bullish Manner : ANAB-US : July 13, 2017
finance.yahoo.com - July 13 at 4:37 PM |
| Robert W. Baird Initiates Coverage on AnaptysBio, Inc. (NASDAQ:ANAB)
www.americanbankingnews.com - July 10 at 7:14 PM |
| AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 10 at 7:06 PM |
| $3.13 Million in Sales Expected for AnaptysBio, Inc. (ANAB) This Quarter
www.americanbankingnews.com - July 9 at 8:13 AM |
| Zacks: Analysts Anticipate AnaptysBio, Inc. (ANAB) Will Post Earnings of -$0.47 Per Share
www.americanbankingnews.com - July 7 at 10:20 PM |
| Zacks: AnaptysBio, Inc. (ANAB) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - July 5 at 9:39 AM |
| AnaptysBio, Inc. – Value Analysis (NASDAQ:ANAB) : June 28, 2017
finance.yahoo.com - June 28 at 4:06 PM |
| AnaptysBio, Inc. breached its 50 day moving average in a Bullish Manner : ANAB-US : June 27, 2017
finance.yahoo.com - June 27 at 3:37 PM |
| Brokerages Expect AnaptysBio, Inc. (ANAB) to Post ($0.47) EPS
www.americanbankingnews.com - June 14 at 6:38 PM |
| Brokerages Expect AnaptysBio, Inc. (ANAB) Will Announce Earnings of -$0.47 Per Share
www.americanbankingnews.com - June 13 at 8:10 PM |
| Why AnaptysBio (ANAB) Could Be Positioned for a Slump
finance.yahoo.com - June 9 at 3:51 PM |
| AnaptysBio to Participate in Upcoming Investor Conferences
finance.yahoo.com - June 1 at 3:47 PM |
| AnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : May 29, 2017
finance.yahoo.com - May 29 at 3:54 PM |
| Zacks: AnaptysBio Inc (ANAB) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - May 29 at 9:06 AM |
| Analysts Expect AnaptysBio Inc (ANAB) Will Post Earnings of -$0.47 Per Share
www.americanbankingnews.com - May 17 at 8:28 AM |
| Equities Analysts Offer Predictions for AnaptysBio Inc's Q2 2017 Earnings (ANAB)
www.americanbankingnews.com - May 17 at 8:08 AM |
| AnaptysBio Inc (ANAB) Releases Earnings Results
www.americanbankingnews.com - May 12 at 11:26 AM |
| AnaptysBio Announces First Quarter 2017 Financial Results and Provides Pipeline Update
finance.yahoo.com - May 11 at 8:49 PM |
| AnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : May 11, 2017
finance.yahoo.com - May 11 at 3:47 PM |
| Zacks: Brokerages Set $37.67 Target Price for AnaptysBio Inc (ANAB)
www.americanbankingnews.com - May 4 at 11:02 PM |
| Stifel Nicolaus Reaffirms "Buy" Rating for AnaptysBio Inc (ANAB)
www.americanbankingnews.com - May 2 at 1:28 PM |
| $1.63 Million in Sales Expected for AnaptysBio Inc (ANAB) This Quarter
www.americanbankingnews.com - April 28 at 5:33 PM |
| -$0.25 Earnings Per Share Expected for AnaptysBio Inc (ANAB) This Quarter
www.americanbankingnews.com - April 26 at 11:44 AM |
| Zacks Investment Research Downgrades AnaptysBio Inc (ANAB) to Sell
www.americanbankingnews.com - April 25 at 6:16 PM |
| AnaptysBio, Inc. – Value Analysis (NASDAQ:ANAB) : April 20, 2017
finance.yahoo.com - April 20 at 3:36 PM |
| AnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : April 19, 2017
finance.yahoo.com - April 19 at 3:31 PM |
| AnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : April 19, 2017
finance.yahoo.com - April 19 at 3:31 PM |
| AnaptysBio's (ANAB) "Outperform" Rating Reaffirmed at Credit Suisse Group AG
www.americanbankingnews.com - April 18 at 4:52 PM |
| Zacks: AnaptysBio Inc (ANAB) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - April 18 at 10:34 AM |
| ETFs with exposure to AnaptysBio, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 5:50 AM |
| AnaptysBio Announces First-In-Human Dosing of ANB019
finance.yahoo.com - April 7 at 5:50 AM |
| AnaptysBio Inc (ANAB) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - April 6 at 9:34 AM |
| JMP Securities Reaffirms "Outperform" Rating for AnaptysBio Inc (ANAB)
www.americanbankingnews.com - April 6 at 9:31 AM |
| AnaptysBio Inc (ANAB) Given New $28.00 Price Target at Wedbush
www.americanbankingnews.com - April 4 at 8:11 AM |
| AnaptysBio Inc (ANAB) to Post Q1 2018 Earnings of ($0.60) Per Share, Wedbush Forecasts
www.americanbankingnews.com - March 31 at 1:05 PM |
| AnaptysBio Inc (ANAB) Earns Outperform Rating from JMP Securities
www.americanbankingnews.com - March 31 at 12:02 PM |
| AnaptysBio Inc (ANAB) Stock Rating Reaffirmed by Wedbush
www.americanbankingnews.com - March 29 at 4:37 PM |
| AnaptysBio Inc (ANAB) Coverage Initiated at JMP Securities
www.americanbankingnews.com - March 26 at 2:25 PM |
 | Coverage initiated on AnaptysBio by Credit Suisse, Wedbush, Stifel and JMP Securities
us.rd.yahoo.com - February 22 at 8:35 PM |
| Coverage initiated on AnaptysBio by Wedbush and Stifel
finance.yahoo.com - February 21 at 3:48 PM |
| AnaptysBio to Present Data from ANB020 Program at Two Upcoming Medical Meetings
finance.yahoo.com - February 21 at 7:54 AM |
 | Robust Start for Pharmaceutical IPOs In 2017
www.investopedia.com - February 6 at 3:17 PM |
 | [$$] Braeburn Pharmaceuticals Puts IPO Plans On Hold
www.wsj.com - February 2 at 8:34 PM |
| [$$] Shares in Two Biotechs Rise Post-IPO
www.wsj.com - January 31 at 8:45 PM |
| AnaptysBio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - January 31 at 8:45 PM |
AnaptysBio (ANAB) Chart for Thursday, July, 27, 2017
